Seer, Inc.

NASDAQ:SEER

Biotechnology

Healthcare
$1.44 +0.29%

+$0.01 today

Market cap
$80.37M
Beta
1.59
P/E (TTM)
-1.4
EPS (TTM)
-$1.26
52W Low $1.65High $2.41

Volume 0.23M

Average 0.32M

SEER Other Financing Activities

Financing cash flows not reported separately.

Seer, Inc.NASDAQ: SEER

Other Financing Activities · Q1 FY2026 · quarter ended Mar 2026

Other financing activities turns positive

Q1 FY2026 other financing activities was $0, compared with -$827K a year earlier. Trailing-twelve-month other financing activities was $23K.

Context

  • Other financing activities amounted to 5.1% of revenue in FY2025, up 2.8 pp from a year earlier.
  • Other financing activities increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly other financing activities holds near $0 or moves back toward the trailing-twelve-month quarterly average of $5.75K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
-$827K-357.6% YoY
LTMMar 2026
$23K+104.5% YoY
Other Financing Activities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+100.0%——
1 year-357.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Financing Activities history

USD · from the cash flow

Latest · FY2025
(827K) USD
Year-over-year change
-357.6%

Other Financing Activities vs competitors

How SEER compares with its peers on the latest reported figures

  • Peers report in different currencies, so other financing activities is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +104.5% is the 5th highest of 15, against a peer median of -91.8%.
  • Other financing activities amounts to 0.2% of revenue for SEER, versus a peer median of 6.5%.
SEER Competitors
Other Financing Activities for SEER and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PHVSPharvaris N.V.LTM Sep 2026€105.84M EUR+1070.0%+135.1%—
STTKShattuck Labs, Inc.LTM Mar 2026$44.22M USD+56072.2%—4421.8%
KYMRKymera Therapeutics, Inc.LTM Jun 2026$40.35M USD-84.2%—38.4%
MLYSMineralys Therapeutics, Inc.LTM Jun 2026$6.6M USD+26280.0%——
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$1.61M USD———
SANASana Biotechnology, Inc.LTM Mar 2026$551K USD-99.7%——
MOLNMolecular Partners AGLTM Mar 2026CHF 413.44K CHF-102.6%——
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$373K USD+108.4%——
CCCCC4 Therapeutics, Inc.LTM Mar 2026$328K USD-40.9%-9.5%0.9%
MNOVMediciNova, Inc.LTM Mar 2026$244.02K USD——40.9%
QSIQuantum-Si incorporatedLTM Mar 2026$222K USD-99.4%—12.0%
SEERSeer, Inc.LTM Mar 2026$23K USD+104.5%—0.2%
PEPGPepGen Inc.LTM Mar 2026$7K USD———
LYELLyell Immunopharma, Inc.LTM Mar 2026$2K USD-300.0%-87.1%6.5%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$0 USD-100.0%—0.0%
GLUEMonte Rosa Therapeutics, Inc.LTM Mar 2026$0 USD-100.0%—0.0%
ANTXAN2 Therapeutics, Inc.LTM Mar 2026$0 USD———
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$0 USD+100.0%—0.0%
NKTXNkarta, Inc.LTM Mar 2026$0 USD-100.0%——
Peer median (excluding SEER) —-91.8%-9.5%6.5%

Competitors are the stored peer set for SEER. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(71.17M)(92.97M)(86.28M)(86.6M)(73.6M)
Depreciation & Amortization2.56M3.94M5.58M6.18M7.25M
Deferred Income Tax1.2M0000
Stock-Based Compensation25.93M33.67M34.42M28.21M15.41M
Change in Working Capital(5.87M)(7.09M)(2.72M)(144K)(579K)
Accounts Receivables(2.5M)(2.87M)302K487K277K
Inventory(3.59M)(1.59M)(1.95M)(2.67M)(2.9M)
Accounts Payables1.6M(1.55M)(987K)3.36M1.06M
Other Working Capital(1.38M)(1.07M)(91K)(1.32M)983K
Other Non-Cash Items1.01M1.66M(10.07M)6.25M7.07M
Operating Cash Flow(46.35M)(60.78M)(59.07M)(46.11M)(44.45M)
Capital Expenditures(6.92M)(10.27M)(7.31M)(3.58M)(1.8M)
Acquisitions (Net)163.96M0000
Purchases of Investments(279.96M)(366.27M)(403.09M)(272.93M)(173.17M)
Sales of Investments116M253.65M448.31M342.03M237.81M
Other Investing Activities(163.96M)170K0343K(1.3M)
Investing Cash Flow(170.88M)(122.72M)37.9M65.86M61.55M
Debt Repayment00000
Common Stock Issued102.96M000458K
Common Stock Repurchased(35K)(20K)(13K)(11.82M)(10.2M)
Dividends Paid00000
Other Financing Activities13.71M3.91M465K321K(827K)
Financing Cash Flow116.63M3.89M452K(11.5M)(10.57M)
Effect of Forex Changes00000
Net Change in Cash(100.59M)(179.61M)(20.71M)8.25M6.53M
Free Cash Flow(53.27M)(71.05M)(66.37M)(49.69M)(46.25M)

Seer, Inc.

NASDAQ:SEER

Intrinsic Alpha fair value

Locked

Current Price

$1.44

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.